Protocol Ledger

NCT03635567 · Phase III · COMPLETED

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-82

Interventional Phase III clinical trial protocol NCT03635567 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-25 Enrollment: 617 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03635567
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)617 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03635567
Protocol FieldVerified Registry Value
NCT IdentifierNCT03635567
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment617 participants (ACTUAL)
Registered Start Date2018-10-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI